Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, China.
Clin Endocrinol (Oxf). 2021 Apr;94(4):700-710. doi: 10.1111/cen.14371. Epub 2020 Dec 26.
In the 8th edition American Joint Committee on Cancer (AJCC) tumour-node-metastasis (TNM) staging system (TNM-8), changes have been made regarding anaplastic thyroid carcinoma (ATC) compared with the 7th edition (TNM-7). The major changes are that anaplastic ATC now has the same T stage definitions as differentiated thyroid cancer, and new staging of IVA and IVB is implemented. However, the clinical impact of the new edition for ATC remains unclear due to scarce and conflicting data. In this study, we compared the AJCC TNM-7 and TNM-8 in the same group of patients.
In this retrospective study, we included patients who were diagnosed with ATC between 2004 and 2015; data were gathered from the Surveillance, Epidemiology and End Results (SEER) database.
Overall survival (OS) was evaluated according to T stage and TNM stage according to the 7th and 8th editions. Kaplan-Meier and log-rank testing was used to analyse OS. The effect of potential predictors was estimated using the Cox regression model.
We included 669 patients in the study. The median age of the cohort was 70 years. During the follow-up, 600 (89.7%) patients died, 528 of whom died of thyroid cancer. The TNM-8 T staging more effectively predicted survival than the 7th edition (proportion of variation explained: 3.53% vs. 1.72%). However, the clinical stage was almost unchanged according to the TNM-8 (proportion of variation explained: 10.69% vs. 10.73%).
The new T classification is an effective predictor of survival for patients with ATC. The results support the use of T definitions as per those of differentiated thyroid cancer. However, whether lymph node metastasis should be taken into account for defining ATC TNM staging should be reconsidered.
在第 8 版美国癌症联合委员会(AJCC)肿瘤-淋巴结-转移(TNM)分期系统(TNM-8)中,与第 7 版(TNM-7)相比,间变性甲状腺癌(ATC)的分期发生了变化。主要变化是,现在将间变性 ATC 的 T 分期定义与分化型甲状腺癌相同,并实施了新的 IVA 和 IVB 分期。然而,由于数据稀缺且存在冲突,新版 ATC 的临床影响仍不清楚。在这项研究中,我们比较了同一组患者的 AJCC TNM-7 和 TNM-8。
在这项回顾性研究中,我们纳入了 2004 年至 2015 年间被诊断为 ATC 的患者;数据来自监测、流行病学和最终结果(SEER)数据库。
根据第 7 版和第 8 版的 T 分期和 TNM 分期评估总生存率(OS)。采用 Kaplan-Meier 和对数秩检验分析 OS。使用 Cox 回归模型估计潜在预测因子的影响。
我们纳入了 669 例患者。队列的中位年龄为 70 岁。在随访期间,600(89.7%)例患者死亡,其中 528 例死于甲状腺癌。与第 7 版相比,第 8 版的 TNM-8 T 分期更能有效预测生存(变化比例解释:3.53%比 1.72%)。然而,根据 TNM-8,临床分期几乎没有变化(变化比例解释:10.69%比 10.73%)。
新的 T 分类是 ATC 患者生存的有效预测因子。结果支持使用分化型甲状腺癌的 T 定义。然而,是否应考虑淋巴结转移来定义 ATC TNM 分期,应重新考虑。